Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In a study of the breast cancer gene GATA3, Sebastian Nijman’s group has identified classes of mutations that are associated with different activities, including differential disease-free patient survival and drug sensitivities. Their findings highlight that some genes can have both tumour suppressive and oncogenic activities.